CordenPharma, a Switzerland-based global Contract Development and Manufacturing Organisation (CDMO), announced on Wednesday that it has entered into an agreement to acquire AmbioPharm, a US-headquartered peptide Active Pharmaceutical Ingredients (API) CDMO.

AmbioPharm adds differentiated peptide manufacturing capabilities to CordenPharma's existing Peptides Platform and expertise. Once combined, these will include advanced linear and fragment-based peptide approaches supported by flexible Solid-Phase Peptide Synthesis (SPPS), Liquid-Phase Peptide Synthesis (LPPS), and hybrid synthesis, as well as CordenPharma's Tag-Assisted Peptide Synthesis (TAPS).

AmbioPharm employs approximately 400 people across its two sites in South Carolina (USA) and Shanghai (China). This acquisition builds on CordenPharma's global facility network of 11 sites in Europe and North America by expanding its US peptide manufacturing capacity and bringing Shanghai-based peptide supply into its operational footprint.

At AmbioPharm's Shanghai campus, CordenPharma says that it will leverage the new state-of-the-art peptide manufacturing facility to support clinical and commercial global peptide supply with significant upstream capacity across SPPS, LPPS and hybrid synthesis, as well as selected downstream capabilities.